MCID: ALL014
MIFTS: 39

Allergic Encephalomyelitis

Categories: Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Allergic Encephalomyelitis

MalaCards integrated aliases for Allergic Encephalomyelitis:

Name: Allergic Encephalomyelitis 52
Experimental Autoimmune Encephalomyelitis 71

Classifications:



External Ids:

UMLS 71 C0014072

Summaries for Allergic Encephalomyelitis

MalaCards based summary : Allergic Encephalomyelitis, also known as experimental autoimmune encephalomyelitis, is related to myelitis and optic neuritis. An important gene associated with Allergic Encephalomyelitis is MBP (Myelin Basic Protein), and among its related pathways/superpathways are Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions and Rheumatoid arthritis. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and spinal cord, and related phenotype is Reduced mammosphere formation.

Wikipedia : 74 Experimental autoimmune encephalomyelitis, sometimes experimental allergic encephalomyelitis (EAE) is an... more...

Related Diseases for Allergic Encephalomyelitis

Diseases related to Allergic Encephalomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
# Related Disease Score Top Affiliating Genes
1 myelitis 30.4 MOG MBP
2 optic neuritis 30.2 PLP1 MOG MBP
3 acute disseminated encephalomyelitis 30.2 MOG MBP
4 autoimmune disease 30.0 PLP1 MOG MBP CCL5 CCL2
5 guillain-barre syndrome 29.9 MOG MBP
6 spinal cord disease 29.9 MOG MBP
7 neuromyelitis optica 29.9 MOG MBP
8 proteasome-associated autoinflammatory syndrome 1 29.4 CCL5 CCL3 CCL2
9 tuberculous meningitis 29.4 CCL3 CCL2
10 central nervous system disease 29.4 PLP1 MOG MBP CCL2
11 tropical spastic paraparesis 29.4 CCL5 CCL3
12 encephalitis 29.1 MOG CCL5 CCL3 CCL2
13 demyelinating disease 28.9 PLP1 MOG MBP CCL5 CCL3 CCL2
14 neuritis 28.9 MOG MBP CCL5 CCL3 CCL2
15 multiple sclerosis 28.5 PLP1 MOG MBP CCL5 CCL3 CCL2
16 autoimmune disease of central nervous system 28.2 PLP1 MOG MBP CCL5 CCL2
17 relapsing-remitting multiple sclerosis 27.5 PLP1 MOG MBP CCL5 CCL3 CCL2
18 pertussis 10.7
19 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.6
20 allergic hypersensitivity disease 10.6
21 cytokine deficiency 10.4
22 encephalopathy 10.4
23 ataxia and polyneuropathy, adult-onset 10.3
24 paraplegia 10.3
25 vaccinia 10.3
26 nervous system disease 10.3
27 orchitis 10.3
28 vasculitis 10.3
29 hereditary neuropathies 10.2 PLP1 MBP
30 uveitis 10.2
31 lymphopenia 10.2
32 measles 10.2
33 epileptic encephalopathy, early infantile, 39 10.2 PLP1 MBP
34 niemann-pick disease, type a 10.2 PLP1 MBP
35 niemann-pick disease 10.2 PLP1 MBP
36 canavan disease 10.1 PLP1 MBP
37 balo concentric sclerosis 10.1 MOG MBP
38 autoimmune optic neuritis 10.1 MOG MBP
39 autoimmune disease of peripheral nervous system 10.1 MOG MBP
40 krabbe disease 10.1 PLP1 MBP
41 rabies 10.1
42 gout 10.1
43 thyroiditis 10.1
44 iridocyclitis 10.1
45 48,xyyy 10.1
46 tremor 10.1
47 chronic inflammatory demyelinating polyradiculoneuropathy 10.1 MBP CCL5
48 polyradiculoneuropathy 10.1 MBP CCL5
49 subacute sclerosing panencephalitis 10.1 MOG MBP
50 meningoencephalitis 10.0 MBP CCL5

Graphical network of the top 20 diseases related to Allergic Encephalomyelitis:



Diseases related to Allergic Encephalomyelitis

Symptoms & Phenotypes for Allergic Encephalomyelitis

GenomeRNAi Phenotypes related to Allergic Encephalomyelitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 8.92 CCL2 CCL3 MOG PLP1

Drugs & Therapeutics for Allergic Encephalomyelitis

Drugs for Allergic Encephalomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 2 106266-06-2 5073
3
Tocopherol Approved, Investigational Phase 1, Phase 2 1406-66-2, 54-28-4 14986
4
Selenium Approved, Investigational, Vet_approved Phase 1, Phase 2 7782-49-2
5
Lamotrigine Approved, Investigational Phase 2 84057-84-1 3878
6
Methyltestosterone Approved Phase 1, Phase 2 58-18-4 6010
7
Testosterone Approved, Experimental, Investigational Phase 1, Phase 2 58-22-0, 481-30-1 6013 10204
8
Testosterone undecanoate Approved, Investigational Phase 1, Phase 2 5949-44-0
9
Testosterone enanthate Approved Phase 1, Phase 2 315-37-7 9416
10
Atorvastatin Approved Phase 2 134523-00-5 60823
11
Interferon beta-1b Approved Phase 2 145155-23-3
12
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
13
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
14 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
15
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
16
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
17
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
18
Simvastatin Approved Phase 2 79902-63-9 54454
19
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
20
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
21
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
22
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-02-9 14985
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
24 Tocotrienol Investigational Phase 1, Phase 2 6829-55-6
25
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
26 Dopamine Agents Phase 2
27 Serotonin Agents Phase 2
28 Dopamine Antagonists Phase 2
29 Serotonin Antagonists Phase 2
30 Micronutrients Phase 1, Phase 2
31 Vitamins Phase 1, Phase 2
32 Trace Elements Phase 1, Phase 2
33 Nutrients Phase 1, Phase 2
34 Calcium, Dietary Phase 2
35 Tocopherols Phase 1, Phase 2
36 Antioxidants Phase 1, Phase 2
37 Tocotrienols Phase 1, Phase 2
38 Vitamin B Complex Phase 1, Phase 2
39 Alpha-lipoic Acid Phase 1, Phase 2
40 Vitamin B9 Phase 1, Phase 2
41 Ginkgo Phase 1, Phase 2
42 Folate Phase 1, Phase 2
43 Thioctic Acid Phase 1, Phase 2
44 Antipsychotic Agents Phase 2
45 Central Nervous System Depressants Phase 2
46 Sodium Channel Blockers Phase 2
47 Anticonvulsants Phase 2
48 Tranquilizing Agents Phase 2
49 Diuretics, Potassium Sparing Phase 2
50 calcium channel blockers Phase 2

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Effects of Short-chain Fatty Acids, Here Sodium Propionate, a Metabolism Product of the Human Gut-microbiome, on Inflammatory and Metabolic Parameters in Patients on Maintenance Hemodialysis - a Pilot Study Unknown status NCT02976688 Phase 2, Phase 3
2 The Effect of MS14 in Association With Risperidone in Treatment of Schizophrenia: A Double Blind Randomized Control Trial Unknown status NCT01083381 Phase 2 MS14;Risperidone
3 Natural Antioxidants in the Treatment of Multiple Sclerosis Completed NCT00010842 Phase 1, Phase 2 Ginkgo biloba;Alpha-lipoic acid;Vitamin E/Selenium;Essential fatty acids
4 Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis Completed NCT01377870 Phase 1, Phase 2
5 A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis: Single Centre, Phase 2 Trial Completed NCT00257855 Phase 2 Lamotrigine
6 Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial Completed NCT00405353 Phase 1, Phase 2 Androgel 10 grams of gel containing 100 mg of testosterone
7 Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis Completed NCT00248378 Phase 1, Phase 2 Smoked Cannabis
8 Explorative Trial to Investigate the Migration Ability of Mesenchymal Bone Marrow Stem Cells (MSC) in the Central Nervous System (CNS) Following Their Intrathecal Administration in Severe Cases of Multiple Sclerosis (MS) Completed NCT00781872 Phase 1, Phase 2
9 SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study ("SWABIMS Follow Up-study") Completed NCT01111656 Phase 2 Interferon beta-1b group;Interferon beta-1b/Atorvastatin group
10 Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis. Completed NCT00942591 Phase 2 Interferon beta 1b;Atorvastatin
11 Double-blind, Placebo-controlled, Randomized Study of the Safety and Tolerability of Isoxsuprine HCL Combined With High Dose Steroid Treatment of Multiple Sclerosis (MS) Relapse Recruiting NCT03752307 Phase 1, Phase 2 Isoxsuprine Hydrochloride;Placebo;Corticosteroid
12 A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage Not yet recruiting NCT03896217 Phase 2 Simvastatin
13 A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline Versus Placebo as Add-on Therapy in Patients Who Are on Treatment With Interferon-beta-1a 44 Mcg Tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis Terminated NCT01134627 Phase 2 Minocycline;Placebo
14 Phase II Study of High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis Withdrawn NCT00939549 Phase 2 Cyclophosphamide/Glatiramer acetate
15 An Open-label, Randomised, Crossover Study to Assess the Relative Bioavailability of Different 2mg Formulations of GSK2018682(S1P1 Agonist) in Healthy Volunteers Completed NCT01466322 Phase 1 GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
16 to Investigate the Maternal Serum IL-17 Levels in Pregnant Women With Intrahepatic Cholestasis of Pregnancy Unknown status NCT01898832
17 Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus in Peripheral Blood of Patients Unknown status NCT02489877
18 Isfahan University of Medical Sciences Completed NCT02696590
19 A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis Completed NCT02647502
20 The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis Recruiting NCT02050646
21 The Role of IL-II in the Development of Autoimmune Response in Multiple Sclerosis Recruiting NCT03735823
22 The Effect of the Ketogenic Diet on Patients With Relapsing Remitting Multiple Sclerosis Recruiting NCT03718247
23 The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With Clinically Isolated Syndrome Measured by Dynamic Contrast Enhanced Magnetic Resonance Imaging Recruiting NCT03451955
24 Evaluation of the Influence of Salt Intake on TH17 Interleukin(IL)-17 Producing CD4+ Helper T Cells in Human Subjects Active, not recruiting NCT02261688
25 Involvement of Immune Cells Derived From the Intestine in Sjogren's Syndrome Not yet recruiting NCT03841318
26 Calorie Restriction as a Novel Therapeutic Tool to Manipulate Immunity and Improve Therapeutic Potential of First Line Drug Treatments During Relapsing Remitting Multiple Sclerosis Not yet recruiting NCT04042415
27 Clinical Relevance of miR-142-3p as Potential Biomarker of Synaptopathy in Multiple Sclerosis Not yet recruiting NCT03999788

Search NIH Clinical Center for Allergic Encephalomyelitis

Genetic Tests for Allergic Encephalomyelitis

Anatomical Context for Allergic Encephalomyelitis

MalaCards organs/tissues related to Allergic Encephalomyelitis:

40
T Cells, Brain, Spinal Cord, B Cells, Bone, Endothelial, Monocytes

Publications for Allergic Encephalomyelitis

Articles related to Allergic Encephalomyelitis:

(show top 50) (show all 11202)
# Title Authors PMID Year
1
Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014-2019. 61
31960801 2020
2
Orexin/hypocretinin in multiple sclerosis and experimental autoimmune encephalomyelitis. 61
31823881 2020
3
Liver kinase B1 depletion from astrocytes worsens disease in a mouse model of multiple sclerosis. 61
31664743 2020
4
Diffusion Kurtosis Imaging maps neural damage in the EAE model of multiple sclerosis. 61
31830588 2020
5
Biological models in multiple sclerosis. 61
31571267 2020
6
NFAT-Specific Inhibition by dNP2-VIVITAmeliorates Autoimmune Encephalomyelitisby Regulation of Th1 and Th17. 61
31737742 2020
7
Enhanced cognitive performance in experimental autoimmune encephalomyelitis mice treated with dimethyl fumarate after the appearance of disease symptoms. 61
31982706 2020
8
C-type lectin receptors Mcl and Mincle control development of multiple sclerosis-like neuroinflammation. 61
31725411 2020
9
Neutrophil-selective deletion of Cxcr2 protects against CNS neurodegeneration in a mouse model of multiple sclerosis. 61
32019585 2020
10
Arid5a, an RNA-Binding Protein in Immune Regulation: RNA Stability, Inflammation, and Autoimmunity. 61
32035762 2020
11
Changes in spinal cord stiffness in the course of experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. 61
31816310 2020
12
Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4+ T Cell Pathogenicity and Suppresses Autoimmunity. 61
31761564 2020
13
IL-9 Controls Central Nervous System Autoimmunity by Suppressing GM-CSF Production. 61
31852750 2020
14
Intranasal Methylprednisolone Effectively Reduces Neuroinflammation in Mice With Experimental Autoimmune Encephalitis. 61
31886871 2020
15
Inhibitors of Myelination and Remyelination, Bone Morphogenetic Proteins, are Upregulated in Human Neurological Disease. 61
32030597 2020
16
Fibrotic scar after experimental autoimmune encephalomyelitis inhibits oligodendrocyte differentiation. 61
31731043 2020
17
Crotoxin down-modulates pro-inflammatory cells and alleviates pain on the MOG35-55-induced experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. 61
31843645 2020
18
MYMD-1, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis. 61
31778849 2020
19
Corrigendum to "Tuftsin-phosphorylcholine attenuate experimental autoimmune encephalomyelitis" [J Neuroimmunol. 2019 Dec 15;337:577070. doi: 10.1016/j.jneuroim.2019.577070. Epub 2019 Oct 24]. 61
31889570 2020
20
Correction: A Tolerogenic Artificial APC Durably Ameliorates Experimental Autoimmune Encephalomyelitis by Directly and Selectively Modulating Myelin Peptide-Autoreactive CD4+ and CD8+ T Cells. 61
31871025 2020
21
Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming. 61
32023446 2020
22
Oligodendrocytes modulate the immune-inflammatory response in EAE via TNFR2 signaling. 61
31785393 2020
23
Vaccines targeting the primary amino acid sequence and conformational epitope of Aβ had distinct effects on neuropathology and cognitive deficits in EAE/AD mice. 61
32034757 2020
24
Noninvasive Brain Delivery and Efficacy of BDNF to Stimulate Neuroregeneration and Suppression of Disease Relapse in EAE Mice. 61
31846344 2020
25
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation. 61
32024760 2020
26
AKT2 maintains brain endothelial claudin-5 expression and selective activation of IR/AKT2/FOXO1-signaling reverses barrier dysfunction. 61
30574832 2020
27
Propranolol diminished severity of rat EAE by enhancing immunoregulatory/protective properties of spinal cord microglia. 61
31689515 2020
28
The contribution of cyclophilin A to immune-mediated central nervous system inflammation. 61
31790981 2020
29
MiR-125a-5p Regulates Vitamin D Receptor Expression in a Mouse Model of Experimental Autoimmune Encephalomyelitis. 61
31428926 2020
30
Role of tissue plasminogen activator in clinical aggravation of experimental autoimmune encephalomyelitis and its therapeutic potential. 61
31955841 2020
31
Serum pro-inflammatory and anti-inflammatory cytokines and the pathogenesis of experimental autoimmune encephalomyelitis. 61
31709666 2020
32
A novel CNS-homing peptide for targeting neuroinflammatory lesions in experimental autoimmune encephalomyelitis. 61
32035108 2020
33
Exercise modulates the levels of growth inhibitor genes before and after multiple sclerosis. 61
32028123 2020
34
Sex dimorphism in an animal model of multiple sclerosis: Focus on pregnenolone synthesis. 61
31958635 2020
35
Impaired Expression of Tetraspanin 32 (TSPAN32) in Memory T Cells of Patients with Multiple Sclerosis. 61
31963428 2020
36
Oligodendroglial connexin 47 regulates neuroinflammation upon autoimmune demyelination in a novel mouse model of multiple sclerosis. 61
31932428 2020
37
A Critical Regulation of Th17 Cell Responses and Autoimmune Neuro-Inflammation by Ginsenoside Rg3. 61
31936879 2020
38
Mesenchymal stem cells as a treatment for multiple sclerosis: a focus on experimental animal studies. 61
31605598 2020
39
Acetylcholine regulates the development of experimental autoimmune encephalomyelitis via the CD4+ cells proliferation and differentiation. 61
31906749 2020
40
Interleukin-17A Serves a Priming Role in Autoimmunity by Recruiting IL-1β-Producing Myeloid Cells that Promote Pathogenic T Cells. 61
32023490 2020
41
Actin-binding protein cortactin promotes pathogenesis of experimental autoimmune encephalomyelitis by supporting leukocyte infiltration into the central nervous system. 61
31911458 2020
42
Spatio-temporal expression profile of NGF and the two-receptor system, TrkA and p75NTR, in experimental autoimmune encephalomyelitis. 61
31996225 2020
43
Monitoring diffuse injury during disease progression in experimental autoimmune encephalomyelitis with on resonance variable delay multiple pulse (onVDMP) CEST MRI. 61
31605825 2020
44
Myelin-specific CD8+ T cells exacerbate brain inflammation in CNS autoimmunity. 61
31573979 2020
45
Synaptic alterations and immune response are sexually dimorphic in a non-pertussis toxin model of experimental autoimmune encephalomyelitis. 61
31499065 2020
46
A GPR174-CCL21 module imparts sexual dimorphism to humoral immunity. 61
31875850 2020
47
Glycyrrhizic acid promotes neural repair by directly driving functional remyelination. 61
31808502 2020
48
Cytokines and Chemokines in the Pathogenesis of Experimental Autoimmune Encephalomyelitis. 61
31907274 2020
49
Ketogenic diet and fasting diet as Nutritional Approaches in Multiple Sclerosis (NAMS): protocol of a randomized controlled study. 61
31898518 2020
50
HIV-1 Tat protein attenuates the clinical course of experimental autoimmune encephalomyelitis (EAE). 61
31830622 2020

Variations for Allergic Encephalomyelitis

Expression for Allergic Encephalomyelitis

Search GEO for disease gene expression data for Allergic Encephalomyelitis.

Pathways for Allergic Encephalomyelitis

GO Terms for Allergic Encephalomyelitis

Cellular components related to Allergic Encephalomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.62 PLP1 MBP

Biological processes related to Allergic Encephalomyelitis according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.88 MBP CCL5 CCL3 CCL2
2 positive regulation of GTPase activity GO:0043547 9.82 CCL5 CCL3 CCL2
3 cytokine-mediated signaling pathway GO:0019221 9.81 CCL5 CCL3 CCL2
4 inflammatory response GO:0006954 9.81 PLP1 CCL5 CCL3 CCL2
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.79 CCL5 CCL3 CCL2
6 chemotaxis GO:0006935 9.78 CCL5 CCL3 CCL2
7 cellular response to tumor necrosis factor GO:0071356 9.77 CCL5 CCL3 CCL2
8 cellular response to interferon-gamma GO:0071346 9.75 CCL5 CCL3 CCL2
9 response to toxic substance GO:0009636 9.74 MBP CCL5 CCL3
10 cell chemotaxis GO:0060326 9.73 CCL5 CCL3 CCL2
11 MAPK cascade GO:0000165 9.71 MBP CCL5 CCL3 CCL2
12 neutrophil chemotaxis GO:0030593 9.67 CCL5 CCL3 CCL2
13 myelination GO:0042552 9.65 PLP1 MBP
14 positive chemotaxis GO:0050918 9.65 CCL5 CCL3
15 cellular response to interleukin-1 GO:0071347 9.65 CCL5 CCL3 CCL2
16 substantia nigra development GO:0021762 9.64 PLP1 MBP
17 cellular response to fibroblast growth factor stimulus GO:0044344 9.63 CCL5 CCL2
18 chemokine-mediated signaling pathway GO:0070098 9.63 CCL5 CCL3 CCL2
19 positive regulation of calcium ion transport GO:0051928 9.62 CCL5 CCL3
20 positive regulation of calcium ion import GO:0090280 9.61 CCL3 CCL2
21 cellular response to organic cyclic compound GO:0071407 9.61 CCL5 CCL3 CCL2
22 negative regulation by host of viral transcription GO:0043922 9.6 CCL5 CCL3
23 positive regulation of natural killer cell chemotaxis GO:2000503 9.55 CCL5 CCL3
24 astrocyte cell migration GO:0043615 9.54 CCL3 CCL2
25 monocyte chemotaxis GO:0002548 9.54 CCL5 CCL3 CCL2
26 axon ensheathment GO:0008366 9.52 PLP1 MBP
27 protein kinase B signaling GO:0043491 9.5 CCL5 CCL3 CCL2
28 lymphocyte chemotaxis GO:0048247 9.43 CCL5 CCL3 CCL2
29 lipopolysaccharide-mediated signaling pathway GO:0031663 9.33 CCL5 CCL3 CCL2
30 eosinophil chemotaxis GO:0048245 9.13 CCL5 CCL3 CCL2
31 macrophage chemotaxis GO:0048246 8.8 CCL5 CCL3 CCL2

Molecular functions related to Allergic Encephalomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.63 CCL5 CCL3 CCL2
2 cytokine activity GO:0005125 9.58 CCL5 CCL3 CCL2
3 chemoattractant activity GO:0042056 9.43 CCL5 CCL3
4 structural constituent of myelin sheath GO:0019911 9.37 PLP1 MBP
5 phospholipase activator activity GO:0016004 9.32 CCL5 CCL3
6 CCR5 chemokine receptor binding GO:0031730 9.26 CCL5 CCL3
7 CCR1 chemokine receptor binding GO:0031726 9.16 CCL5 CCL3
8 chemokine activity GO:0008009 9.13 CCL5 CCL3 CCL2
9 CCR chemokine receptor binding GO:0048020 8.8 CCL5 CCL3 CCL2

Sources for Allergic Encephalomyelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....